Table 2.

Summarizes patient’s treatment regimens.

Name of treatment regimen	Number of cycles	β-hCG level (mlU/mL) *	β-hCG level (mlU/mL) **	Persistent disease detected by imaging
EMA/CO	11	28,725.0	1.1	•persistent pulmonary nodules
EMA/EP	5	22	<0.6	•suspicious lesion at the top of the vagina •persistent pulmonary disease
TP/TE	6	799	<0.6	•enlarged pulmonary nodules
FAEV	4	23	<0.6	•persistent, enlarged, and new multiple pulmonary nodules in both lobes
ICE	4	385	70	•new right mediastinal node
TRC105	4	70	354	•hilar lymphadenopathy enlarged
Pembrolizumab	6	480	2.6	•hilar lymphadenopathy*** •pulmonary nodules***

EMA/CO etoposide, methotrexate, actinomycin-D, cyclophosphamide and vincristine, EMA/EP etoposide, methotrexate, actinomycin-D, cyclophosphamide, vincristine, substituting cyclophosphamide and vincristine for cisplatin and etoposide on Day 8, TP/TE paclitaxel, cisplatin/paclitaxel, etoposide, FAEV floxuridine, dactinomycin, etoposide and vincristine, ICE ifosfamide, carboplatin and etoposide.

^*Upon initiation of treatment [results from first treatment day or prior lab test].

^**Upon when treatment was ended [results from the final treatment day or subsequent lab test].

^***Detected twenty-two months from final Pembrolizumab cycle.